Biotechnology

Abu Dhabi Health Delegation Concludes Inaugural Visit to China, Opening New Pathways to Advance AI, Precision Medicine and Next-Gen Therapies

ABU DHABI, UAE, Oct. 18, 2026 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has concluded its inaugural health and life sciences mission to China, advancing priority areas of collaboration designed to accelerate the translation ...

2026-10-18 01:54 1213

The World Egg and Sperm Bank (TWESB) Joins IVI Institute to Expand Access to Reproductive Solutions

SCOTTSDALE, Ariz., Oct. 15, 2026 /PRNewswire/ -- IVI Institute, the global leader in fertility care, today announced that The World Egg and Sperm Bank (TWESB), a trusted provider of donor egg and donor sperm services, has joined its global group. This acquisition expands access to high quality re...

2026-10-15 19:51 1078

Brii Biosciences Unveils BRiSC™, an siRNA Therapeutics Discovery Platform

Proprietary BRiSC™ platform to advance the discovery and development of next-generation dual-targeting siRNA medicines Initial focus on prevalent metabolic dysfunctions where complex disease biology and overlapping comorbidities will benefit from coordinated modulation of multiple therapeutic ta...

2026-10-15 19:30 1309

CCTV+: Workshop on Green Control Technology for Corn Pests and Diseases in the Lancang-Mekong River Basin Successfully Held in Hanoi, Vietnam

BEIJING, Oct. 15, 2026 /PRNewswire/ -- From September 21 to 24, a workshop on Green Control Technology for Corn Pests and Diseases in the Lancang–Mekong River Basin was successfully held in Hanoi, Vietnam. The event was organized by the Institute of Plant Protection (IPP), Chinese Academy of Agri...

2026-10-15 16:04 4331

Continuity Biosciences Awarded $9.6 Million Grant to Advance Ultra-Long-Acting Implant for HIV Prevention

Funding supports development of a subcutaneous implant designed to deliver HIV prevention medicine for multiple years from a single placement, advancing toward an IND submission and initiation of a first-in-human Phase 1 study BRADENTON, Fla. and SEATTLE, Oct. 14, 2026 /PRNewswire/ -- Continuity ...

2026-10-14 20:00 1453

NueCell Bio Joins CIRM's Industry Resource Partner Program to Support California's Stem Cell and Gene Therapy Innovators

SAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- NueCell Bio, a translational development partner that helps advance cell therapies from scientific discovery to GMP readiness, announced today it has joined the Industry Resource Partnership (IRP) Program of the California Institute for Regenerative Medici...

2026-10-14 15:00 1822

Telix Highlights Pivotal Trials in Prostate, Brain and Renal Cancers and Next Generation Theranostics at EANM

MELBOURNE, Australia and INDIANAPOLIS, Oct. 14, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that 20 company-related abstracts will be presented at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM) to be held in ...

2026-10-14 13:00 2438

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026, to be held October 20–22 at the ADNEC Centre in Abu Dhabi, the United Arab Emirates. Shannon Cheung, Co-Founder and Vice Chairman of Likang, will join a pa...

2026-10-14 10:25 2052

Paradigm Therapeutics, Inc. Nominated for the Second Straight Year for the Prestigious 2026 Prix Galien USA "Best Start-Up" Award for SD-101 (Zorblesia™), a Topical Therapy for Treating the Entire Skin Surface of Patients with Epidermolysis Bullosa (EB)

SD-101 (Zorblesia™) is the First Topical Therapy Developed to Treat Wounds and Lesions Across the Entire Skin Surface of All Epidermolysis Bullosa (EB) Subtypes This second consecutive nomination places our company and focus on Epidermolysis Bullosa among a select group of visionaries shaping th...

2026-10-14 04:20 2494

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

* Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables * Leverages Waters' unique ability to take an AI-directed experiment from the research bench ...

2026-10-13 20:00 1979

Ailux Appoints Lloyd S. Miller, M.D., Ph.D., as Chief Medical Officer

* Dr. Miller will lead the advancement of the company's AI-native biologics toward first-in-human trials, with initial clinical entry targeted for 2027 * He will also establish a U.S. clinical and research site to complement the company's research capabilities in Shanghai and the U.K. SHANGHAI...

2026-10-13 20:00 2301

Kelun-Biotech to Present Multiple Study Results at ESMO 2026

CHENGDU, China, Oct. 13, 2026 /PRNewswire/ -- The 2026 European Society for Medical Oncology (ESMO) Congress will be held in Madrid, Spain, from October 23 to 27. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) will present results from multiple clini...

2026-10-13 19:23 2307

Rona Therapeutics enters into global license agreement with Roche for ALK7-targeting RNAi therapy for obesity and metabolic diseases

SANTA BARBARA, Calif., Oct. 13, 2026 /PRNewswire/ -- Rona Therapeutics today announced it has granted Roche (SIX: RO, ROG; OTCQX: RHHBY) an exclusive worldwide license for Rona's investigational RNAi candidate targeting activin receptor-like kinase 7 (ALK7) utilizing the company's proprietary ext...

2026-10-13 15:00 5240

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted its investigational new drug (IND) application for AK0406, a long-acting antiviral drug-Fc conjugate (AFC), enabling the company...

2026-10-13 09:00 2958

GCCL and LabConnect Sign MOU to Expand Global Clinical Trial Collaboration

Linking North American and Asia-Pacific Capabilities to Support Joint Sales and Project Execution SEOUL, South Korea and RALEIGH, N.C., Oct. 13, 2026 /PRNewswire/ -- GCCL, a South Korea-based leading global clinical trial central laboratory represented by CEO Kwan-goo Cho, announced today that i...

2026-10-13 08:15 3219

T-MAXIMUM's B7-H3-Targeted Allogeneic CAR-T MT027 Receives FDA Clearance for Phase 2 Study in Brain Metastases from Lung and Breast Cancer

BEIJING, Oct. 12, 2026 /PRNewswire/ -- T-MAXIMUM PHARMACEUTICAL ("T-MAXIMUM") today announced that the U.S. Food and Drug Administration (FDA) has cleared the company to initiate a Phase 2 clinical study of MT027, its internally developed, B7-H3-targeted universal (allogeneic) CAR-T therapy, for ...

2026-10-12 18:50 1742

New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026

MILAN, Oct. 10, 2026 /PRNewswire/ -- From October 06 to 08, 2026, Kexing Biopharm (688136.SH) exhibited at CPHI Milan 2026, showcasing its global innovative drug pipeline, co-developed biosimilars, and a broad portfolio of products commercialized in overseas markets. During the event, the Company...

2026-10-10 16:06 4782

Invetech & MeMed win 2026 Good Design Award Gold for MeMed Key™

Award recognizes innovation, design excellence, and impact in Engineering Design SAN DIEGO, Oct. 9, 2026 /PRNewswire/ -- Invetech, a product realization company that designs, engineers and manufactures fully customizable platforms, announced that its work on the MeMed Key™ has been recognized wit...

2026-10-10 04:00 2666

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune di...

2026-10-09 11:22 4787

Everest Medicines Appoints Two Veteran mRNA Cancer Vaccine Scientists to Advance Global Clinical Development

* Lakshmi Srinivasan, PhD, former Executive Director and Head of Oncology Translational Medicine at Moderna, and Brandon Coder, PhD, former Research & Early Translational Lead, Cancer Vaccines at Moderna, join Everest Medicines * Appointments support continued advancement of Everest's mRNA pip...

2026-10-09 10:15 5489
12345 ... 185